Literature DB >> 3102382

Prospective study on humoral immune response induced by fungal infection in patients with hematologic malignancies.

I Kostiala, E Elonen, P Ylipaavalniemi, A A Kostiala.   

Abstract

To evaluate the immune response in an immunosuppressed population, antibodies against commercially available Candida albicans antigens were prospectively studied during 37 episodes of acute stomatitis caused by C. albicans and 36 episodes complicated by deep-seated mycoses in 62 adult patients with hematologic malignancies. During uncomplicated stomatitis in patients with acute leukemia, the mean peak IgM, IgG and IgA class enzyme-linked immunosorbent assay (ELISA) units differed significantly from the basic level preceding fungal infection. Mean time until peak values was 2.7-3.8 weeks after diagnosis of stomatitis. During systemic mycoses the antibody response was similar. Among patients with other hematologic malignancies, predominantly lymphomas, several were terminally ill and responded infrequently by antibody production. Similar results were given by Ouchterlony immunodiffusion and counterimmunoelectrophoresis. Thus, patients with acute leukemia showed an antibody response to fungal infection; the peak values, however, were somewhat delayed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102382     DOI: 10.1007/bf01643958

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

1.  ORAL THRUSH, OR ACUTE PSEUDOMEMBRANOUS CANDIDIASIS; A CLINICOPATHOLOGIC STUDY OF FORTY-FOUR CASES.

Authors:  T LEHNER
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1964-07

2.  Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia.

Authors:  E M Hersh; J P Whitecar; K B McCredie; G P Bodey; E J Freireich
Journal:  N Engl J Med       Date:  1971-11       Impact factor: 91.245

3.  Inhibition of the primary immune response in man by anti-metabolites.

Authors:  E M Hersh; P P Carbone; V G Wong; E J Freireich
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

4.  Serial enzyme-linked immunosorbent assays for antibody to Candida antigens during induction chemotherapy for acute leukemia.

Authors:  R A Greenfield; M J Bussey; J L Stephens; J M Jones
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

5.  Immunodeficient CBA/N mice respond effectively to Candida albicans.

Authors:  E W Carrow; R F Hector; J E Domer
Journal:  Clin Immunol Immunopathol       Date:  1984-12

6.  Detection by counterimmunoelectrophoresis of anti-Candida precipitins in sera from cancer patients.

Authors:  R L Hopfer; D Gröschel
Journal:  Am J Clin Pathol       Date:  1979-08       Impact factor: 2.493

7.  Dissemination of yeasts after gastrointestinal inoculation in antibiotic-treated mice.

Authors:  M J Kennedy; P A Volz
Journal:  Sabouraudia       Date:  1983-03

8.  Isolated lymphadenitis caused by Candida albicans in a patient with acute leukemia.

Authors:  J Epstein; C U Tuazon
Journal:  Arch Intern Med       Date:  1981-11

9.  Diagnostic value of monitoring kinetics of antibody responses in candidiasis by a solid-phase radioimmunoassay.

Authors:  H Mauch
Journal:  Am J Clin Pathol       Date:  1983-02       Impact factor: 2.493

10.  Murine model of pulmonary mucormycosis in cortisone-treated mice.

Authors:  A R Waldorf; C Halde; N A Vedros
Journal:  Sabouraudia       Date:  1982-09
View more
  3 in total

1.  Value of detection of antibodies to Candida albicans germ tube in the diagnosis of systemic candidosis.

Authors:  G Quindós; J Pontón; R Cisterna; D W Mackenzie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

Review 2.  Diagnosis of invasive mycoses in severely immunosuppressed patients.

Authors:  R Rüchel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

3.  Serial study of C-reactive protein during fungal esophagitis and enterocolitis.

Authors:  I Kostiala; A A Kostiala; E Elonen
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.